#USA #Boston #Takeda #TetraScience #Scientific AI

TetraScience Launches SAIL Program with Takeda

On October 24, 2025, TetraScience, a leading company in scientific data and artificial intelligence, launched its innovative Scientific AI Lighthouse (SAIL) program, establishing Takeda as its founding partner. This groundbreaking initiative aims to transform the research and development (R&D) processes within the biopharmaceutical industry, utilizing advanced AI technologies and data analytics to enhance efficiency and productivity.

The Role of Takeda

As the first founding partner of the SAIL program, Takeda gains priority access to TetraScience’s comprehensive suite of data and AI tools. This partnership is poised to accelerate AI-driven drug discovery, reduce CMC (Chemistry, Manufacturing, and Controls) cycle times, enable in silico modeling, and boost scientists’ productivity through agentic AI solutions. The broader goal is to empower biopharmaceutical organizations to streamline their operations, introducing more products to market at lower costs and with diminished risks while enhancing the overall quality of drug candidates.

For decades, biopharmaceutical R&D productivity has been hindered by fragmented datasets, custom workflows, manual processes, and one-off project strategies that fail to scale effectively. The SAIL model from TetraScience addresses these challenges head-on by introducing an integrated set of capabilities developed specifically for the AI era.

Key Components of the SAIL Program

1. Scientific Data Foundry: This innovative platform disaggregates scientific data entrenched in siloed vendor systems into atomic components (experimental measurements, metadata, derived results, and instrument telemetry). These components are organized into AI-driven schemas, taxonomies, and ontologies, making them reusable and sharable, thus protecting biopharmaceutical data from vendor lock-in and improving compliance with regulations and audit readiness.

2. Scientific Use Case Factory: This aspect of the program is designed to productize and mass-produce AI-based use cases and workflows. By combining AI-driven data from the Foundry, TetraScience can create standardized, repeatable, and configurable processes. The factory will roll out hundreds of common scientific use cases throughout the R&D and production value chain, making them widely accessible to the biopharmaceutical industry.

3. Tetra AI: This feature provides semi-autonomous and fully autonomous capabilities that aid scientists in navigating complex, multi-step processes within R&D. Tetra AI will proactively deliver relevant data from a variety of experiments, uncover broader chemical and biological patterns that manual workflows might overlook, and synthesize large inputs simultaneously to facilitate quicker and more confident decision-making.

4. Sciborgs: To ensure successful adoption of the SAIL program, TetraScience deploys teams of science-engineers, dubbed "Sciborgs." These professionals work at the intersection of science, data, and AI, facilitating cultural and operational transformation through immersion in client teams and ensuring sustainable implementation of Scientific AI.

Together, these four elements foster a self-reinforcing cycle of value creation. Every dataset refined in the Foundry enhances the reliability of future workflows; each use case produced in the Factory informs Tetra AI's learning process; and every new ontology bridges workflows across domains. The outcome is a scientific innovation flywheel—greater usage leads to improved data quality, resulting in higher-quality insights that enable newer and more powerful use scenarios.

Insights from Leadership

Nicole Glazer, Takeda’s Head of R&D Data, Digital Technology, expressed, "Embedding AI and digital technologies into the R&D value chain is a strategic focal point for Takeda’s future. Our data-driven R&D approach will shorten discovery times, accelerate target identification, and improve our capabilities to design better therapeutic candidates."
Jim Villa, Global Head of Research Strategy & Operations at Takeda, added, "By transforming how our scientists access, analyze, and share research data, we unlock new levels of productivity and enable AI-driven insights through a connected online data environment. We not only enhance productivity but also foster innovation by leveraging data and agentic AI to integrate information swiftly, uncover new connections, define better hypotheses, and accelerate innovation in our drug discovery engine."
Patrick Grady, CEO of TetraScience, highlighted the long-standing challenge in the pharmaceutical industry due to the Eroom's Law, which notes that drug development costs double approximately every nine years. He stated, "By shifting the industry from unsustainable, custom data projects and workflows to scalable, AI-driven scientific data and workflows, we can help reshape the curve of Eroom's Law, accelerating discoveries, shortening cycle times, and expanding the frontiers of what science can achieve. Our partnership with Takeda exemplifies the future of the industry.”

About TetraScience

TetraScience is a pioneering force in scientific data and AI. The Scientific Data Foundry converts scientific 'raw materials' into AI-based data, while the Scientific Use Case Factory industrializes AI-driven workflows for R&D and production. Tetra AI connects the Foundry and Factory, providing agentic capabilities that guide scientists through complex workflows, uncover cross-domain insights, and accelerate scientific outcomes. Supported by partners like Insight Partners, Impetus Ventures, Underscore_VC, and Alkeon Capital, and trusted by leading biopharmaceutical companies and global partnerships—including NVIDIA, Databricks, Snowflake, and Microsoft—TetraScience is proactively building new platforms for the scientific industry in the AI era. For more information, visit tetrascience.com.